vs
Side-by-side financial comparison of Ametek (AME) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Ametek is the larger business by last-quarter revenue ($2.0B vs $708.5M, roughly 2.8× Medpace Holdings, Inc.). Ametek runs the higher net margin — 19.9% vs 19.1%, a 0.9% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 13.4%). Ametek produced more free cash flow last quarter ($527.3M vs $188.1M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 7.3%).
AMETEK, Inc. is an American multinational conglomerate and global designer and manufacturer of electronic instruments and electromechanical devices with headquarters in the United States and over 150 sites worldwide.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
AME vs MEDP — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $2.0B | $708.5M |
| Net Profit | $398.6M | $135.1M |
| Gross Margin | 36.0% | — |
| Operating Margin | 25.3% | 21.6% |
| Net Margin | 19.9% | 19.1% |
| Revenue YoY | 13.4% | 32.0% |
| Net Profit YoY | 2.9% | 15.5% |
| EPS (diluted) | $1.73 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.0B | $708.5M | ||
| Q3 25 | $1.9B | $659.9M | ||
| Q2 25 | $1.8B | $603.3M | ||
| Q1 25 | $1.7B | $558.6M | ||
| Q4 24 | $1.8B | $536.6M | ||
| Q3 24 | $1.7B | $533.3M | ||
| Q2 24 | $1.7B | $528.1M | ||
| Q1 24 | $1.7B | $511.0M |
| Q4 25 | $398.6M | $135.1M | ||
| Q3 25 | $371.4M | $111.1M | ||
| Q2 25 | $358.4M | $90.3M | ||
| Q1 25 | $351.8M | $114.6M | ||
| Q4 24 | $387.3M | $117.0M | ||
| Q3 24 | $340.2M | $96.4M | ||
| Q2 24 | $337.7M | $88.4M | ||
| Q1 24 | $310.9M | $102.6M |
| Q4 25 | 36.0% | — | ||
| Q3 25 | 36.3% | — | ||
| Q2 25 | 35.8% | — | ||
| Q1 25 | 36.1% | — | ||
| Q4 24 | 36.6% | — | ||
| Q3 24 | 36.0% | — | ||
| Q2 24 | 36.0% | — | ||
| Q1 24 | 34.1% | — |
| Q4 25 | 25.3% | 21.6% | ||
| Q3 25 | 25.8% | 21.5% | ||
| Q2 25 | 26.0% | 20.9% | ||
| Q1 25 | 26.3% | 20.3% | ||
| Q4 24 | 26.6% | 23.4% | ||
| Q3 24 | 26.1% | 21.1% | ||
| Q2 24 | 25.8% | 19.9% | ||
| Q1 24 | 24.0% | 20.4% |
| Q4 25 | 19.9% | 19.1% | ||
| Q3 25 | 19.6% | 16.8% | ||
| Q2 25 | 20.2% | 15.0% | ||
| Q1 25 | 20.3% | 20.5% | ||
| Q4 24 | 22.0% | 21.8% | ||
| Q3 24 | 19.9% | 18.1% | ||
| Q2 24 | 19.5% | 16.7% | ||
| Q1 24 | 17.9% | 20.1% |
| Q4 25 | $1.73 | $4.65 | ||
| Q3 25 | $1.60 | $3.86 | ||
| Q2 25 | $1.55 | $3.10 | ||
| Q1 25 | $1.52 | $3.67 | ||
| Q4 24 | $1.67 | $3.67 | ||
| Q3 24 | $1.47 | $3.01 | ||
| Q2 24 | $1.45 | $2.75 | ||
| Q1 24 | $1.34 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $458.0M | $497.0M |
| Total DebtLower is stronger | $2.3B | — |
| Stockholders' EquityBook value | $10.6B | $459.1M |
| Total Assets | $16.1B | $2.0B |
| Debt / EquityLower = less leverage | 0.21× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $458.0M | $497.0M | ||
| Q3 25 | $439.2M | $285.4M | ||
| Q2 25 | $619.7M | $46.3M | ||
| Q1 25 | $399.0M | $441.4M | ||
| Q4 24 | $374.0M | $669.4M | ||
| Q3 24 | $396.3M | $656.9M | ||
| Q2 24 | $396.6M | $510.9M | ||
| Q1 24 | $373.8M | $407.0M |
| Q4 25 | $2.3B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $10.6B | $459.1M | ||
| Q3 25 | $10.5B | $293.6M | ||
| Q2 25 | $10.4B | $172.4M | ||
| Q1 25 | $10.0B | $593.6M | ||
| Q4 24 | $9.7B | $825.5M | ||
| Q3 24 | $9.6B | $881.4M | ||
| Q2 24 | $9.3B | $763.6M | ||
| Q1 24 | $9.0B | $671.5M |
| Q4 25 | $16.1B | $2.0B | ||
| Q3 25 | $16.2B | $1.8B | ||
| Q2 25 | $15.3B | $1.6B | ||
| Q1 25 | $14.9B | $1.9B | ||
| Q4 24 | $14.6B | $2.1B | ||
| Q3 24 | $14.8B | $2.1B | ||
| Q2 24 | $14.8B | $1.9B | ||
| Q1 24 | $14.9B | $1.8B |
| Q4 25 | 0.21× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.22× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $584.3M | $192.7M |
| Free Cash FlowOCF − Capex | $527.3M | $188.1M |
| FCF MarginFCF / Revenue | 26.4% | 26.6% |
| Capex IntensityCapex / Revenue | 2.9% | 0.6% |
| Cash ConversionOCF / Net Profit | 1.47× | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $1.7B | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $584.3M | $192.7M | ||
| Q3 25 | $440.9M | $246.2M | ||
| Q2 25 | $359.1M | $148.5M | ||
| Q1 25 | $417.5M | $125.8M | ||
| Q4 24 | $550.0M | $190.7M | ||
| Q3 24 | $487.2M | $149.1M | ||
| Q2 24 | $381.4M | $116.4M | ||
| Q1 24 | $410.2M | $152.7M |
| Q4 25 | $527.3M | $188.1M | ||
| Q3 25 | $420.0M | $235.5M | ||
| Q2 25 | $329.8M | $142.4M | ||
| Q1 25 | $394.5M | $115.8M | ||
| Q4 24 | $498.3M | $183.0M | ||
| Q3 24 | $460.9M | $138.5M | ||
| Q2 24 | $360.0M | $103.5M | ||
| Q1 24 | $382.6M | $147.2M |
| Q4 25 | 26.4% | 26.6% | ||
| Q3 25 | 22.2% | 35.7% | ||
| Q2 25 | 18.5% | 23.6% | ||
| Q1 25 | 22.8% | 20.7% | ||
| Q4 24 | 28.3% | 34.1% | ||
| Q3 24 | 27.0% | 26.0% | ||
| Q2 24 | 20.8% | 19.6% | ||
| Q1 24 | 22.0% | 28.8% |
| Q4 25 | 2.9% | 0.6% | ||
| Q3 25 | 1.1% | 1.6% | ||
| Q2 25 | 1.6% | 1.0% | ||
| Q1 25 | 1.3% | 1.8% | ||
| Q4 24 | 2.9% | 1.4% | ||
| Q3 24 | 1.5% | 2.0% | ||
| Q2 24 | 1.2% | 2.4% | ||
| Q1 24 | 1.6% | 1.1% |
| Q4 25 | 1.47× | 1.43× | ||
| Q3 25 | 1.19× | 2.22× | ||
| Q2 25 | 1.00× | 1.65× | ||
| Q1 25 | 1.19× | 1.10× | ||
| Q4 24 | 1.42× | 1.63× | ||
| Q3 24 | 1.43× | 1.55× | ||
| Q2 24 | 1.13× | 1.32× | ||
| Q1 24 | 1.32× | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AME
| Transferred At Point In Time | $1.1B | 54% |
| Electronic Instruments Group | $620.1M | 31% |
| Transferred Over Time | $294.6M | 15% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
